| Literature DB >> 22609786 |
Nura Suleiman Gwaram1, Hapipah Mohd Ali, Hamid Khaledi, Mahmood Ameen Abdulla, A Hamid A Hadi, Thong Kwai Lin, Chai Lay Ching, Cher Lin Ooi.
Abstract
A series ofEntities:
Mesh:
Substances:
Year: 2012 PMID: 22609786 PMCID: PMC6269056 DOI: 10.3390/molecules17055952
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Reaction pathway for the coordinated complexes.
Figure 1The molecular X-ray structure of 8 and 9 showing the atom labeling scheme (50% probability ellipsoids). Hydrogen atoms are drawn as spheres of arbitrary radius.
Selected bond lengths [Ǻ] and Selected bond angles [°] for compounds 8 and 9.
| 8 | 9 | ||||||
|---|---|---|---|---|---|---|---|
| Zn1 | Br1 | 2.4036(4) | Zn1 | N1 | 2.1752(18) | ||
| Zn1 | Br2 | 2.4172(4) | Zn1 | N2 | 2.0752(18) | ||
| Zn1 | N1 | 2.243(3) | Zn1 | N3 | 2.217(2) | ||
| Zn1 | N2 | 2.076(2) | Zn1 | N4 | 1.9681(18) | ||
| Zn1 | N3 | 2.331(2) | Zn1 | N5 | 1.9698(19) | ||
| Br1 | Zn1 | Br2 | 116.905(15) | N1 | Zn1 | N3 | 154.18(7) |
| N1 | Zn1 | Br1 | 92.48(6) | N2 | Zn1 | N1 | 75.30(7) |
| N1 | Zn1 | Br2 | 95.00(6) | N2 | Zn1 | N3 | 79.64(8) |
| N1 | Zn1 | N3 | 151.50(8) | N4 | Zn1 | N1 | 97.48(7) |
| N2 | Zn1 | Br1 | 133.79(6) | N4 | Zn1 | N2 | 133.47(8) |
| N2 | Zn1 | Br2 | 108.28(6) | N4 | Zn1 | N3 | 95.22(7) |
| N2 | Zn1 | N1 | 73.92(9) | N4 | Zn1 | N5 | 113.13(8) |
| N2 | Zn1 | N3 | 79.37(9) | N5 | Zn1 | N1 | 96.56(7) |
| N3 | Zn1 | Br1 | 99.01(6) | N5 | Zn1 | N2 | 113.35(8) |
| N3 | Zn1 | Br2 | 102.71(5) | N5 | Zn1 | N3 | 98.97(8) |
| C1 | N1 | Zn1 | 128.0(2) | C1 | N1 | Zn1 | 126.71(14) |
| C5 | N1 | Zn1 | 113.25(18) | C5 | N1 | Zn1 | 114.26(14) |
| C6 | N2 | Zn1 | 120.85(19) | C6 | N2 | Zn1 | 120.19(15) |
| C8 | N2 | Zn1 | 115.86(19) | C8 | N2 | Zn1 | 114.51(17) |
| C9 | N3 | Zn1 | 100.28(17) | C9 | N3 | Zn1 | 100.2(2) |
| C13 | N3 | Zn1 | 115.48(17) | C10 | N3 | Zn1 | 112.0(2) |
| C6 | N2 | C8 | 122.7(2) | C11 | N3 | Zn1 | 107.3(3) |
| C8 | N2 | Zn1 | 115.86(19) | C9' | N3 | Zn1 | 104.0(2) |
| C9 | N3 | C13 | 109.5(2) | C11 | N3 | Zn1 | 112.3(2) |
| C1 | N1 | C5 | 118.7(3) | C12 | N4 | Zn1 | 162.3(2) |
| C10 | N3 | C13 | 107.5(2) | C13 | N5 | Zn1 | 175.5(2) |
Crystal data for compounds 8 and 9.
| 8 | 9 | |
|---|---|---|
| Empirical formula | C13H19Br2N3OZn | C13H17N5S2Zn |
| Formula weight | 458.50 | 372.81 |
| Temperature/K | 100(2) | 100(2) |
| Crystal system | monoclinic | monoclinic |
| Space group | P21/n |
|
| a/Å | 9.8290(2) | 13.7663(2) |
| b/Å | 14.0218(2) | 9.4949(2) |
| c/Å | 12.1371(2) | 13.8089(2) |
| β/° | 106.9180(10) | 109.9460(10) |
| Volume/Å3 | 1600.35(5) | 1696.68(5) |
| Z | 4 | 4 |
| ρcalcmg/mm3 | 1.903 | 1.459 |
| m/mm−1 | 6.527 | 1.693 |
| F(000) | 904 | 768 |
| Crystal size/mm3 | 0.33 × 0.25 × 0.11 | 0.35 × 0.31 × 0.19 |
| 2Θ range for data collection | 4.56 to 54° | 5.14 to 54° |
| Reflections collected | 12535 | 15059 |
| Independent reflections | 3496[ | 3707[ |
| Data/restraints/parameters | 3496/0/182 | 3707/14/225 |
| Goodness-of-fit on F2 | 1.028 | 1.015 |
| Final R indexes [I >= 2σ (I)] | ||
| Final R indexes [all data] | ||
| Largest diff. peak/hole/e Å−3 | 0.679/−0.466 | 0.455/−0.428 |
First level antibacterial screening Disc diffusion assay.
| Compound | MRSA 0804-25 | MRSA 0807-7 | AC 0612-7 | AC 0903-21 | KB 71 | KB 83 | PA 45 | PA 104 |
|---|---|---|---|---|---|---|---|---|
| 1 | 6 | 6 | 0 | 0 | 0 | 0 | 5 | 6 |
| 2 | 5 | 5 | 0 | 0 | 0 | 0 | 5 | 5 |
| 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 21 | 22 | 7 | 7 | 0 | 0 | 8 | 8 |
| 5 | 24 | 23 | 9 | 8 | 0 | 0 | 11 | 19 |
| 6 | 22 | 23 | 9 | 8 | 0 | 0 | 10 | 10 |
| 7 | 23 | 22 | 10 | 10 | 0 | 0 | 8 | 8 |
| 8 | 21 | 20 | 10 | 9 | 0 | 0 | 9 | 9 |
| 9 | 23 | 23 | 9 | 8 | 0 | 0 | 10 | 9 |
| 10 | 22 | 22 | 7 | 7 | 0 | 0 | 10 | 9 |
| Control (DMSO) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Second level antibacterial screening.
| Minimum inhibitory concentration (MIC; µg/mL)/minimum bactericidal concentration (MBC; µg/mL) | ||||||||
|---|---|---|---|---|---|---|---|---|
| MRSA 0804-25 | MRSA 0807-7 | AC 0612-7 | AC 0903-21 | KB 71 | KB 83 | PA 45 | PA 104 | |
| 1-3 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| 4 | 0.7/2.9 | 1.5/2.9 | 93.8/750 | 93.8/750 | 375/750 | 375/750 | 187.5/750 | 187.5/750 |
| 5 | 0.7/2.9 | 0.7/2.9 | 93.8/750 | 93.8/750 | 187.5/750 | 187.5/750 | 187.5/750 | 187.5/750 |
| 6 | 1.5/5.9 | 1.5/5.9 | 93.8/375 | 93.8/375 | 375/750 | 375/750 | 187.5/750 | 187.5/750 |
| 7 | 1.5/5.9 | 1.5/5.9 | 93.8/375 | 93.8/375 | 187.5/750 | 187.5/750 | 187.5/750 | 187.5/750 |
| 8 | 1.5/5.9 | 1.5/2.9 | 93.8/750 | 93.8/750 | 375/750 | 375/750 | 187.5/750 | 187.5/750 |
| 9 | 1.5/5.9 | 1.5/23.4 | 187.5/750 | 187.5/750 | 375/750 | 375/750 | 187.5/750 | 187.5/750 |
| 10 | 2.9/46.9 | 2.9/46.9 | 187.5/750 | 187.5/750 | 375/750 | 375/750 | 187.5/750 | 187.5/750 |
| DMSO | 375/>375 | 375/>375 | 375/>375 | 375/>375 | 375/>375 | 375/>375 | 375/>375 | 375/>375 |
n.d. = not determined.
Varying responses of the eight MRSA clinical strains towards the seven selected Schiff-base complexes in the disc diffusion assay.
| Compounds | MRSA 0805-21 | MRSA 0806-1 | MRSA 0807-1 | MRSA 0807-19 | MRSA 0808-35 | MRSA 0809-15 | MRSA 0809-25 | MRSA 0809-38 |
|---|---|---|---|---|---|---|---|---|
|
| 23 | 24 | 0 | 23 | 0 | 22 | 22 | 21 |
|
| 23 | 24 | 0 | 25 | 0 | 23 | 23 | 23 |
|
| 24 | 22 | 0 | 22 | 0 | 21 | 21 | 22 |
|
| 24 | 20 | 0 | 21 | 0 | 19 | 20 | 20 |
|
| 25 | 23 | 0 | 24 | 0 | 21 | 21 | 22 |
|
| 23 | 23 | 0 | 22 | 0 | 23 | 24 | 23 |
|
| 22 | 22 | 0 | 22 | 0 | 22 | 22 | 22 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Figure 2Histogram for the 10 MRSA clinical strains of Schiff-base complexes.
Antibiogram of the ten clinical strains of MRSA used in the antibacterial analysis.
| Strain No | E | CN | LZD | MUP | RD | DA | TEC | CIP | NET | TE | VA | FD | OX | SXT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRSA 0805-21 | R | R | S | S | S | S | S | R | R | R | S | S | R | R |
| MRSA 0806-1 | R | R | S | S | S | S | S | R | R | R | S | S | R | R |
| MRSA 0807-1 | R | R | S | S | S | S | S | R | R | R | S | S | R | R |
| MRSA 0807-19 | R | R | S | S | S | S | S | R | I | S | S | S | R | S |
| MRSA 0808-35 | R | R | S | S | S | S | S | I | I | R | S | S | R | R |
| MRSA 0809-15 | R | R | S | S | S | S | S | R | R | R | S | S | R | R |
| MRSA 0809-24 | R | R | S | S | S | S | S | R | R | R | S | S | R | R |
| MRSA 0809-38 | R | R | S | S | S | S | S | R | R | R | S | S | R | S |
| MRSA 0807-7 | R | R | S | S | S | S | S | R | I | R | S | S | R | R |
| MRSA 0804-25 | R | R | S | S | S | S | S | R | S | S | S | S | R | S |
E = erythromycin; GN = gentamycin; LZD-linozolid acid; MUP = muciprocin; RD- rifampicin; DA = clindamycin; TEC = teicoplanin; CIP = ciproflozaxin; NET = netilmycin; TE = tetracycline; VA = vancomycin; FD = fusicidic acid; OX = oxacilin; SXT = Trimethoprim-sulfamethaxazole; R = resistant; S = sensitive; I = intermediate resistant.
Figure 3Photograph showing the antibacterial (MRSA 0804-25-A,B,C) and (MRSA 0807-7-a,b,c) screening.